嗜酸细胞性胃炎的研究进展

doi:10.3969/j.issn.1006-7795.2024.03.026

摘要/Abstract

摘要： 嗜酸细胞性胃炎（eosinophilic gastritis，EoG）是临床少见疾病，近年发病率增加，发病机制尚不明确。该病临床及内镜下表现多样，缺乏特征性，目前尚无统一的诊断标准，临床医师及病理科医师提高对该病的警惕，是及早诊断并治疗的关键。近年生物制剂在该病的治疗中进展较快，但研究尚少；饮食消除、抑酸剂、糖皮质激素等常规的多种治疗在该病中的研究亦较少。嗜酸细胞性胃炎值得多方面的进一步研究。

关键词: 嗜酸细胞性胃炎, 发病机制, 临床表现, 治疗进展

Abstract: Eosinophilic gastritis (EoG) is an uncommon digestive disorder with an unclear cause. The prevalence of EoG has been on the rise in recent years. Clinically, EoG have no specific manifestations with most patients presenting with diverse features and endoscopic findings. There are no standardized diagnostic criteria for EoG as yet. Thus, vigilance among clinicians and pathologists is crucial for early diagnosis and treatment of EoG. While the use of biologics for EoG has witnessed significant advancements in recent years, there are few studies on this topic. Conventional treatments for EoG include food elimination diet, acid suppressants and glucocorticoids. Currently, research on standard therapeutic interventions is limited, which warrants further research to understand various aspects of EoG.

Key words: eosinophilic gastritis, pathogenesis, clinical manifestation, treatment advances

中图分类号:

R573

李中恕. 嗜酸细胞性胃炎的研究进展[J]. 首都医科大学学报, 2024, 45(3): 548-555.

Li Zhongshu. Understanding eosinophilic gastritis: new research insights[J]. Journal of Capital Medical University, 2024, 45(3): 548-555.

参考文献

［1］ Caldwell J M, Collins M H, Stucke E M, et al. Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome［J］. J Allergy Clin Immunol, 2014, 134(5): 1114－1124.
［2］ Pesek R D, Reed C C, Muir A B, et al. Increasing rates of diagnosis, substantial Co-occurrence, and variable treatment patterns of eosinophilic gastritis, gastroenteritis, and colitis based on 10-year data across a multicenter consortium［J］. Am J Gastroenterol, 2019, 114(6): 984－994.
［3］ Dellon E S, Gonsalves N, Abonia J P, et al. International consensus recommendations for eosinophilic gastrointestinal disease nomenclature［J］. Clin Gastroenterol Hepatol, 2022, 20(11): 2474－2484.e3.
［4］ Jensen E T, Martin C F, Kappelman M D, et al. Prevalence of eosinophilic gastritis, gastroenteritis, and colitis: estimates from a national administrative database［J］. J Pediatr Gastroenterol Nutr, 2016, 62(1): 36－42.
［5］ Licari A, Votto M, Scudeller L, et al. Epidemiology of nonesophageal eosinophilic gastrointestinal diseases in symptomatic patients: a systematic review and meta-analysis［J］. J Allergy Clin Immunol Pract, 2020, 8(6): 1994－2003.e2.
［6］ Allen-Brady K, Colletier K J, Woller S, et al. Eosinophilic gastritis and enteritis are increased in families with eosinophilic esophagitis［J］. Am J Gastroenterol, 2023, 118(2): 263－268.
［7］ Jensen E T, Dai X, Kodroff E, et al. Early life exposures as risk factors for non-esophageal eosinophilic gastrointestinal diseases［J］. Clin Res Hepatol Gastroenterol, 2023, 47(7): 102170.
［8］ Gonsalves N, Doerfler B, Zalewski A, et al. Prospective study of an amino acid-based elemental diet in an eosinophilic gastritis and gastroenteritis nutrition trial［J］. J Allergy Clin Immunol, 2023, 152(3): 676－688.
［9］ Prussin C, Lee J, Foster B. Eosinophilic gastrointestinal disease and peanut allergy are alternatively associated with IL-5+ and IL－5－ T(H)2 responses［J］. J Allergy Clin Immunol, 2009, 124(6): 1326－1332.e6.
［10］ Kinoshita Y, Furuta K, Ishimura N, et al. Elevated plasma cytokines in Japanese patients with eosinophilic esophagitis and gastroenteritis［J］. Digestion, 2012, 86(3): 238－243.
［11］ Quan S F, Sedgwick J B, Nelson M V, et al. Corticosteroid resistance in eosinophilic gastritis—relation to in vitro eosinophil survival and interleukin 5［J］. Ann Allergy, 1993, 70(3): 256－260.
［12］ Jiang H, Harris M B, Rothman P. IL-4/IL-13 signaling beyond JAK/STAT［J］. J Allergy Clin Immunol, 2000, 105(6 Pt 1): 1063－1070.
［13］ Shoda T, Rochman M, Collins M H, et al. Molecular analysis of duodenal eosinophilia［J］. J Allergy Clin Immunol, 2023, 151(4):1027－1039.
［14］ Shoda T, Wen T, Caldwell J M, et al. Molecular, endoscopic, histologic, and circulating biomarker-based diagnosis of eosinophilic gastritis: multi-site study［J］. J Allergy Clin Immunol, 2020, 145(1): 255－269.
［15］ Youngblood B A, Leung J, Falahati R, et al. Discovery, function, and therapeutic targeting of siglec-8［J］. Cells, 2020, 10(1): 19.
［16］ Quinn L, Nguyen B, Menard K C, et al. IgG4+ cells are increased in the gastrointestinal tissue of pediatric patients with active eosinophilic gastritis and duodenitis and decrease in remission［J］. Dig Liver Dis, 2023, 55(1): 53－60.
［17］ Zhang J, Hou S Y, Chi X Q, et al. Role of SNAP25 on the occurrence and development of eosinophilic gastritis［J］. Medicine: Baltimore, 2023, 102(29): e34377.
［18］ Furuta G T, Fillon S A, Williamson K M, et al. Mucosal microbiota associated with eosinophilic esophagitis and eosinophilic gastritis［J］. J Pediatr Gastroenterol Nutr, 2023, 76(3): 347－354.
［19］ Facchin S, Calgaro M, Pandolfo M, et al. Salivary microbiota composition may discriminate between patients with eosinophilic oesophagitis (EoE) and non-EoE subjects［J］. Aliment Pharmacol Ther, 2022, 56(3): 450－462.
［20］ Shah S C, Tepler A, Peek R M J, et al. Association between Helicobacter pylori exposure and decreased odds of eosinophilic esophagitis——a systematic review and Meta analysis［J］. Clin Gastroenterol Hepatol, 2019, 17(11): 2185—2198.e3.
［21］ Papadopoulos A A, Tzathas C, Polymeros D, et al. Symptomatic eosinophilic gastritis cured with Helicobacter pylori eradication［J］. Gut, 2005, 54(12): 1822.
［22］ Nakamura A, Iwaya Y, Iwaya M, et al. Eosinophilic gastroenteritis complicated with Helicobacter pylori infection unresponsive to eradication therapy［J］. Intern Med, 2014, 53(18): 2061－2065.
［23］ Kliewer K L, Murray P C, Collins M H, et al. Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial［J］. Lancet Gastroenterol Hepatol, 2023, 8(9): 803－815.
［24］ Ko H M, Morotti R A, Yershov O, et al. Eosinophilic gastritis in children: clinicopathological correlation, disease course, and response to therapy［J］. Am J Gastroenterol, 2014, 109(8): 1277－1285.
［25］ Li K W, Ruan G C, Liu S, etal. Long-term prognosis and its associated predictive factors in patients with eosinophilic gastroenteritis［J］. World J Gastroenterol, 2024, 30(2): 146－157.
［26］ Kodjo K K, 魏波, 尉秀清, 等. 以幽门梗阻为表现的嗜酸性粒细胞胃肠炎2例报道及文献复习［J］. 新医学, 2016, 47(7): 462－467.
［27］徐琪, 汤净. 酷似胃癌的嗜酸细胞性胃炎并幽门梗阻一例［J］. 新医学, 2017, 48(5): 360－364.
［28］布娅·米然别克, 巴图, 美丽克扎提·安扎尔, 等. 误诊为黏膜下肿瘤的嗜酸性粒细胞性胃炎患者的临床特征及内镜特点分析［J］. 中国处方药, 2017, 15(10): 1－3.
［29］陈美燕, 戴益琛, 潘桂兰. 以腹水为主要表现的嗜酸细胞性胃肠炎48例临床分析［J］. 海南医学, 2019, 30(2): 229-231.
［30］ Parida L. Eosinophilic gastritis within gastric heterotopia of meckel's diverticulum［J］. Eur J Gastroenterol Hepatol, 2022, 34(3): 358.
［31］ Kinoshita Y, Furuta K J, Ishimaura N, et al. Clinical characteristics of Japanese patients with eosinophilic esophagitis and eosinophilic gastroenteritis［J］. J Gastroenterol, 2013, 48(3): 333－339.
［32］ Collins M H. Histopathologic features of eosinophilic esophagitis and eosinophilic gastrointestinal diseases［J］. Gastroenterol Clin North Am, 2014, 43(2): 257－268.
［33］ Papadopoulou A, Amil D J, Auth M K, et al. Joint Espghan/Naspghan guidelines on childhood eosinophilic gastrointestinal disorders beyond eosinophilic esophagitis［J］. J Pediatr Gastroenterol Nutr, 2024, 78(1): 122－152.
［34］ Lopes Vendrami C, Kelahan L D, Escobar D J, et al. Imaging findings of eosinophilic gastrointestinal diseases in adults［J］. Curr Probl Diagn Radiol, 2023, 52(2): 139－147.
［35］ Hirano I, Collins M H, King E, et al. Prospective endoscopic activity assessment for eosinophilic gastritis in a multisite cohort［J］. Am J Gastroenterol, 2022, 117(3): 413－423.
［36］ Fujiwara Y, Tanoue K, Higashimori A, et al. Endoscopic findings of gastric lesions in patients with eosinophilic gastrointestinal disorders［J］. Endosc Int Open, 2020, 8(12): E1817－E1825.
［37］ Lee J M, Kim R J, Lim J S, et al. Eosinophilic gastritis with linear arrays of pseudopolyps in the antrum treated with exclusive enteral nutrition［J］. J Pediatr Gastroenterol Nutr, 2022, 74(5): e127.
［38］ Saad A J, Genta R M, Turner K O, et al. Do general pathologists assess gastric and duodenal eosinophilia?［J］. Arch Pathol Lab Med, 2023, 147(9): 1086－1092.
［39］ Genta R M, Dellon E S, Turner K O. Non-oesophageal eosinophilic gastrointestinal diseases are undersuspected clinically and underdiagnosed pathologically［J］. Aliment Pharmacol Ther, 2022, 56(2): 240－250.
［40］ Chehade M, Kamboj A P, Atkins D, et al. Diagnostic delay in patients with eosinophilic gastritis and/or duodenitis: a population-based study［J］. J Allergy Clin Immunol Pract, 2021, 9(5): 2050－2059.e20.
［41］ Pesek R D, Greuter T, Lopez-Nunez O, et al. Clinicopathologic correlations in eosinophilic gastrointestinal disorders［J］. J Allergy Clin Immunol Pract, 2021, 9(9): 3258－3266.
［42］ Nagashima S R, Yamamoto M, Inuzuka Y, et al. Tolerability and safety of a newelimination diet for pediatric eosinophilic gastritis and duodenitis［J］. Allergol Int, 2023, 72(2): 306－315.
［43］ Ng L Q, Loh W, Ong J X, et al. Clinical, histopathological features and efficacy of elimination diet and proton-pump inhibitor therapy in achieving histologicalremission in Asian children with eosinophilic gastritis［J］. J Paediatr Child Health, 2022, 58(7): 1244－1250.
［44］ Fujita Y J, Tominaga K, Tanaka T K A, et al. Eosinophilic duodenal ulcer exacerbation after Helicobacter pylori eradication in a 14-year-old boy［J］. Tohoku J Exp Med, 2022, 257(2): 153－156.
［45］ Han D, Lee J K. Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab［J］. Ann Allergy Asthma Immunol, 2018, 121(6): 742－743.
［46］ García Martínez A, Campos Gonzaga L, Mateos Millán D, et al. Reslizumab in gastroenterology: experience in a patient with eosinophilic gastroenteritis［J］. Gastroenterol Hepatol, 2022, 45(Suppl 1): 147－148.
［47］ Kuang F L, De Melo M S, Makiya M, et al. Benralizumab completely depletes gastrointestinal tissue eosinophils and improves symptoms in eosinophilic gastrointestinal disease［J］. J Allergy Clin Immunol Pract, 2022, 10(6): 1598－1605.e2.
［48］ Sia T, Bacchus L, Tanaka R, et al. Dupilumab can induce remission of eosinophilic gastritis and duodenitis: a retrospective case series［J］. Clin Transl Gastroenterol, 2024, 15(1): e00646.
［49］ Dellon E S, Peterson K A, Murray J A, et al. Anti-siglec-8 antibody for eosinophilic gastritis and duodenitis［J］. N Engl J Med, 2020, 383(17): 1624－1634.
［50］ Fu J, Sia T, Solecki R, et al. Clinical and histologic remission achieved with upadacitinib in a patient with refractory eosinophilic gastritis and duodenitis［J］. J Allergy Clin Immunol Pract, 2024: S2213－2198(24)00205.
［51］ Tsuji A, Hiramatsu K, Namikawa S, et al. A rare case of eosinophilic gastritis induced by nivolumab therapy for metastatic melanoma［J］. Clin J Gastroenterol, 2022, 15(5): 876－880.
［52］ Iwamuro M, Murakami T, Tanaka T, et al. Eosinophilic gastritis in a patient previously treated with dupilumab［J］. Case Rep Gastrointest Med, 2020, 2020: 6381670.
［53］ Quinn L A, Burger C, Nguyen B, et al. Natural histories and disease complications in a cohort of 151 children with gastric or duodenal eosinophilia［J/OL］. Am J Gastroenterol, 2024. ［2024-03-13］. https://pubmed.ncbi.nlm.nih.gov/38174865/.
［54］ Fang S B, Song Y Q, Zhang S X, et al. Retrospective study of budesonide in children with eosinophilic gastroenteritis［J］. Pediatr Res, 2019, 86(4): 505－509.
［55］ Copeland B H, Aramide O O, Wehbe S A, et al. Eosinophilia in a patient with cyclical vomiting: a case report［J］. Clin Mol Allergy, 2004, 2(1): 7.
［56］ Pan F Y, Smale M, Rennie M, et al. Eosinophilic gastroenteritis causing pyloric stenosis: a rare manifestation［J］. ACG Case Rep J, 2024, 11(3): e01292.
［57］陈莹. 氯雷他定在嗜酸细胞性胃炎患者中的应用效果与安全性研究［J］. 中国现代药物应用, 2019, 13(16): 101－102.
［58］ Nakagome S, Koizumi E, Goto O, et al. A successful treatment case of refractory hemorrhagic ulcer with eosinophilic gastritis by endoscopic hand suturing［J］. DEN Open, 2023, 3(1): e207.